外伤性视神经病变（TON）是指由外伤引起的视神经损伤，导致部分或完全丧失视力。主要治疗方案,比如激素治疗和手术，功效有限。垂体腺苷酸环化酶激活多肽38（PACAP38），一种功能性内源性神经保护肽,已经成为一种有前途的治疗剂。在这项研究中,我们使用大鼠视网膜神经节细胞（RGC）外泌体作为纳米囊泡，通过外泌体锚定肽CP05（EXOPACAP38）递送PACAP38。EXOPACAP38在体外和体内显示出比PACAP38更大的摄取效率。结果表明，在大鼠TON模型中，EXOPACAP38显着提高了RGC存活率和视网膜神经纤维层厚度。此外，EXOPACAP38显著促进损伤后轴突再生和视神经功能。这些发现表明EXOPACAP38可以用作治疗选择，并且可能对TON患者具有治疗意义。
Traumatic optic neuropathy (TON) refers to optic nerve damage caused by trauma, leading to partial or complete loss of vision. The primary treatment options, such as hormonal therapy and surgery, have limited efficacy. Pituitary adenylate cyclase-activating polypeptide 38 (PACAP38), a functional endogenous neuroprotective peptide, has emerged as a promising therapeutic agent. In this study, we used rat retinal ganglion cell (RGC) exosomes as nanosized vesicles for the delivery of PACAP38 loaded via the exosomal anchor peptide CP05 (EXO PACAP38 ). EXO PACAP38 showed greater uptake efficiency in vitro and in vivo than PACAP38. The results showed that EXO PACAP38 significantly enhanced the RGC survival rate and retinal nerve fiber layer thickness in a rat TON model. Moreover, EXO PACAP38 significantly promoted axon regeneration and optic nerve function after injury. These findings indicate that EXO PACAP38 can be used as a treatment option and may have therapeutic implications for patients with TON.
PDF(Pubmed)